Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 - sprookjes - yvandenbroek - TriplyDB

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

http://www.wikidata.org/entity/Q28588292

about

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 Self-association of human PCSK9 correlates with its LDLR-degrading activity Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels The PCSK9 decade Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 PCSK9 and triglyceride-rich lipoprotein metabolism From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Profile of evolocumab and its potential in the treatment of hyperlipidemia Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia Molecular biology of PCSK9: its role in LDL metabolism Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future The proprotein convertases and their implication in sterol and/or lipid metabolism Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells In vivo evidence that furin from hepatocytes inactivates PCSK9 Conversion of low density lipoprotein-associated phosphatidylcholine to triacylglycerol by primary hepatocytes PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease)The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke.Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.Differential proteomics profiling identifies LDPs and biological functions in high-fat diet-induced fatty livers.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

P2860

6be66f76bcb0b20e81ab5a44d34c0edfaa398d46 ff84a278912e9fa1b36b7aa711c0a88999b2e78a

P248

Q21136366-39EB7748-5FC7-4555-A871-CF01F24EA2B0 Q24294486-345C9133-4F5A-4BC5-9D36-0EF2FE4284C5 Q24299848-106CFF1F-0883-4B88-89DE-6378CCA6E1C4 Q24300790-1CF846A5-DE84-4E21-A3A1-42414DD718C7 Q24301411-B8D2E88A-FD5E-4ABF-8A7F-CED8817C205F Q24306591-2EA0CEAC-98D5-45D7-9050-419D190AD225 Q24311328-037DFC28-34B2-4259-B3F1-E0F1DBE110B5 Q24313575-68CA6A87-7031-434C-A469-531FFF450567 Q24615397-D5925EEA-C475-4205-A43D-51D13D04CD49 Q24646644-D3C8FB88-3DF8-40FA-9A29-A8ED469A06AB Q24652495-F4E2CDAD-11C4-4BDB-9E8F-22CF76728B0A Q24654997-8A1E93AD-DA9B-4E70-A676-38B52F0CD502 Q24658351-F0226B0D-48B5-4A99-B3B4-D632C32900A2 Q26786549-6C529076-7D37-490E-81EE-32F4F77CED35 Q26796287-4AB04C46-0DAC-4446-9924-F05FF007CFFE Q26997647-0F70DFC7-0F43-448B-9383-F8596F6A4C61 Q27003094-285617EF-8541-4E31-BD33-81AA459DD95A Q27004235-F8E8499B-A130-457C-94B6-77D9FF771D31 Q27009477-2A9CEE9F-C249-4658-B340-6FB08D000305 Q27013494-0C099B5D-A4CA-450D-97A2-364214B203FA Q27488922-FDABFFC6-005F-4B49-B553-2B48CBCA7AAF Q27644461-DA2BBCBE-528B-4BCD-BECC-E86A7CDF9FE7 Q27647905-1BB05DC6-1F32-4E22-8F60-50033A2DAA12 Q27655476-90D48EC6-57D8-4DC3-B581-D7A607E4070A Q27665195-88ADAF00-23AC-4E33-B7D5-C321FD17FAA6 Q28082561-EB193882-3DFF-4011-AED9-1BF0B61252D3 Q28083595-AFBAD732-E73B-4615-BFEF-27A6E428735A Q28258161-2599F00A-4F1C-423A-A77F-99463DAC74DC Q28304381-8766C8B1-345D-4A5B-A1A0-7208573A6E89 Q28504537-086121E9-B35E-4477-8B08-9CC756F88CCB Q28506881-95598919-FD93-4E71-AB3B-474F9570865D Q28586625-FB058694-23A7-46CD-B7E9-5DAA9A32CB5B Q28587541-F9590CE6-81DF-4BAA-A67F-0644C33D9BE3 Q28756853-1D4C0483-25EB-4DC3-BFA5-F12DD3A1911E Q30498009-390C36F4-0239-4796-8B54-20492001A40A Q30541820-767A9C76-91E0-4E61-BE13-3FC3725E516E Q33302900-0A4E60E9-9C95-4B19-BB6B-645B67D9ACD8 Q33380457-8EC6FAA6-437A-4C16-8AE0-744F3A0B7AD2 Q33568000-1DCF461A-F39C-4E88-9099-E729784087A1 Q33577851-B721D8D6-0CB6-4CA1-9847-65AD0AD09302

P2860

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

http://www.wikidata.org/entity/Q28588292

description

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

article publié dans les Procee ...... f the United States of America

@fr

artículu científicu espublizáu en 2005

@ast

im April 2005 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2005/04/12)

@sk

vědecký článek publikovaný v roce 2005

@cs

wetenschappelijk artikel (gepubliceerd op 2005/04/12)

@nl

наукова стаття, опублікована у квітні 2005

@uk

name

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@ast

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@en

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@nl

type

label

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@ast

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@en

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@nl

prefLabel

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@ast

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@en

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@nl

P1433

Q28588292-5286B531-ACED-4274-BAE0-3C810B9FD30A

P1476

Q28588292-EADFC974-88B3-4054-A6A0-FB5EA8BD2E75

P2093

Q28588292-0EA2CBEC-6159-4DF5-BF23-316F6D1B62A6

Q28588292-2333B6C4-066C-4BA1-B29B-252D0AAA7F2E

Q28588292-603E939A-BABB-4D43-8146-CC456504BB2B

Q28588292-6DE67B3F-A467-42A2-9253-88709BF9AC7B

Q28588292-77D7AC41-1188-47A5-8F45-2DCE3FAF93B5

Q28588292-7CD7D34C-4C60-49A5-92D1-C23B98240A9C

Q28588292-892D9A7B-A562-4042-BC81-7113B147E517

Q28588292-8BB058C0-EACA-4A63-B073-10189E4AE6B9

Q28588292-D770ADE8-5D7B-437D-AED2-598BBB131AE5

P2860

Q28588292-14741FFF-299C-4F8A-A2CE-A3C00FFDBB07

Q28588292-22766E17-0033-4100-B56E-46D8E50FD954

Q28588292-456836F3-80DF-4D7A-A198-C6B5AEF6DC09

Q28588292-4FC5CB5F-EB2B-470E-8DDB-B35E0C37D401

Q28588292-5B45852E-FCDD-420D-ABCF-33D5A3B6B9B9

Q28588292-7B1DD662-7C50-4778-B882-C7E48C9CDD54

Q28588292-7BA51FE6-76C7-4613-9AF0-71C2F0C027E2

Q28588292-82D680C1-77D4-4A75-9C31-8A3A1190CEC9

Q28588292-8F4BF7FB-F25A-4FBA-9877-587671BE00FB

Q28588292-A3E4945F-6144-473E-A583-AF89B93AF80E

P304

Q28588292-529FE184-A0BF-47A0-AA86-C6473D3E25CE

P31

Q28588292-00E01C4B-5692-4A95-98EE-1E59AD13D278

P3181

Q28588292-863B4263-F02F-4F8D-89B1-E8C9FA26358B

P356

Q28588292-2CF687A7-46DC-4958-A4B7-3738C1C78894

P407

Q28588292-FF904C4C-1F2F-4D0C-975B-6B78CE3E5E74

P433

Q28588292-69A6B4CB-3F68-453D-975B-D539BC7D27D2

P478

Q28588292-B5EAC72C-C4AF-4E85-83D5-7AFF7A3F45A6

P577

Q28588292-B3BFF313-78B9-4BCB-B585-78789CBD90B5

P5875

Q28588292-BC801842-A175-4C6A-A72B-5D02F10CB39A

P698

Q28588292-9663386B-C7A4-4223-A515-C758DC5079C3

P921

Q28588292-0DB61254-7BA3-45E6-A3AB-ACFEBEC7D141

Q28588292-5F526148-7495-48C7-B55A-00D430601A23

P932

Q28588292-76518A85-F5B1-460F-B16F-AF28D34FF49B

P3181

P356

PNAS.0501652102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

@en

P2093

David E. Curtis

http://www.w3.org/2001/XMLSchema#string

Jay D. Horton

http://www.w3.org/2001/XMLSchema#string

Norma N. Anderson

http://www.w3.org/2001/XMLSchema#string

Rita Garuti

http://www.w3.org/2001/XMLSchema#string

Robert E. Hammer

http://www.w3.org/2001/XMLSchema#string

Shirya Rashid

http://www.w3.org/2001/XMLSchema#string

Y. K. Ho

http://www.w3.org/2001/XMLSchema#string

Young-Ah Moon

http://www.w3.org/2001/XMLSchema#string

Yuriy Bashmakov

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia

The LDL receptor gene family: (un)expected signal transducers in the brain

Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

P304

5374–5379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

899854

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0501652102

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7931260

http://www.w3.org/2001/XMLSchema#string

P698

15805190

http://www.w3.org/2001/XMLSchema#string

P921

Low density lipoprotein receptor

Proprotein convertase subtilisin/kexin type 9

P932

556275

http://www.w3.org/2001/XMLSchema#string